The Technical AnalystExchange: OSE Sector: Pharmaceuticals Industry: Drug Manufacturers—Specialty & Generic
Photocure ASA Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
1.84% NOK55.40
Europe/Oslo / 26 apr 2024 @ 16:25
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 501.65 mill |
| EPS: | -1.240 |
| P/E: | -44.68 |
| Earnings Date: | May 15, 2024 |
| SharesOutstanding: | 27.11 mill |
| Avg Daily Volume: | 0.0812 mill |
| RATING 2024-04-26 |
|---|
| A+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Buy | |
| Return On Asset: | Buy | |
| DE: | Neutral | |
| P/E: | Strong Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -44.68 | sector: PE -43.24 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.27x |
| Company: PE -44.68 | industry: PE 165.19 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
NOK29.49 (-46.77%) NOK-25.91 |
| Date: 2024-04-27 |
| Expected Trading Range (DAY) |
|---|
|
NOK 53.16 - 57.64 ( +/- 4.04%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
-10.00
Sell
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | NOK55.40 (1.84% ) |
| Volume | 0.0909 mill |
| Avg. Vol. | 0.0812 mill |
| % of Avg. Vol | 111.89 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PHO.OL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:38 | sell | NOK61.10 | N/A | Active |
|---|
PHO.OL
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.